E
Syndax Pharmaceuticals, Inc.
SNDX
$10.56
-$0.45-4.09%
E
Sell
2/26/2025Downgrade
Syndax Pharmaceuticals, Inc. (SNDX) was downgraded to E+ from D- on 2/26/2025 due to a decline in the total return index, valuation index and volatility index.
Syndax Pharmaceuticals, Inc. (SNDX) was downgraded to E+ from D- on 2/26/2025 due to a decline in the total return index, valuation index and volatility index.
D
Sell
12/26/2024Upgraded
Syndax Pharmaceuticals, Inc. (SNDX) was upgraded to D- from E+ on 12/26/2024 due to an increase in the valuation index.
Syndax Pharmaceuticals, Inc. (SNDX) was upgraded to D- from E+ on 12/26/2024 due to an increase in the valuation index.
E
Sell
12/10/2024Downgrade
Syndax Pharmaceuticals, Inc. (SNDX) was downgraded to E+ from D- on 12/10/2024 due to a decline in the total return index, volatility index and valuation index.
Syndax Pharmaceuticals, Inc. (SNDX) was downgraded to E+ from D- on 12/10/2024 due to a decline in the total return index, volatility index and valuation index.
D
Sell
11/25/2024Upgraded
Syndax Pharmaceuticals, Inc. (SNDX) was upgraded to D- from E+ on 11/25/2024 due to an increase in the valuation index.
Syndax Pharmaceuticals, Inc. (SNDX) was upgraded to D- from E+ on 11/25/2024 due to an increase in the valuation index.
E
Sell
11/8/2024Downgrade
Syndax Pharmaceuticals, Inc. (SNDX) was downgraded to E+ from D- on 11/8/2024 due to a decline in the volatility index and valuation index.
Syndax Pharmaceuticals, Inc. (SNDX) was downgraded to E+ from D- on 11/8/2024 due to a decline in the volatility index and valuation index.
D
Sell
1/4/2024Upgraded
Syndax Pharmaceuticals, Inc. (SNDX) was upgraded to D- from E+ on 1/4/2024 due to an increase in the volatility index and total return index.
Syndax Pharmaceuticals, Inc. (SNDX) was upgraded to D- from E+ on 1/4/2024 due to an increase in the volatility index and total return index.
E
Sell
12/14/2023Downgrade
Syndax Pharmaceuticals, Inc. (SNDX) was downgraded to E+ from D- on 12/14/2023 due to a decline in the volatility index, valuation index and total return index.
Syndax Pharmaceuticals, Inc. (SNDX) was downgraded to E+ from D- on 12/14/2023 due to a decline in the volatility index, valuation index and total return index.
D
Sell
11/28/2023Upgraded
Syndax Pharmaceuticals, Inc. (SNDX) was upgraded to D- from E+ on 11/28/2023 due to an increase in the volatility index.
Syndax Pharmaceuticals, Inc. (SNDX) was upgraded to D- from E+ on 11/28/2023 due to an increase in the volatility index.
E
Sell
11/8/2023Downgrade
Syndax Pharmaceuticals, Inc. (SNDX) was downgraded to E+ from D- on 11/8/2023 due to a noticeable decline in the total return index, efficiency index and volatility index. Net income declined 14.64% from -$44.62M to -$51.15M, and total capital declined 10.22% from $402.14M to $361.06M.
Syndax Pharmaceuticals, Inc. (SNDX) was downgraded to E+ from D- on 11/8/2023 due to a noticeable decline in the total return index, efficiency index and volatility index. Net income declined 14.64% from -$44.62M to -$51.15M, and total capital declined 10.22% from $402.14M to $361.06M.
D
Sell
10/11/2023Downgrade
Syndax Pharmaceuticals, Inc. (SNDX) was downgraded to D- from D on 10/11/2023 due to a major decline in the total return index, volatility index and efficiency index. Net income declined 8.48% from -$41.13M to -$44.62M, and total capital declined 7.89% from $436.56M to $402.14M.
Syndax Pharmaceuticals, Inc. (SNDX) was downgraded to D- from D on 10/11/2023 due to a major decline in the total return index, volatility index and efficiency index. Net income declined 8.48% from -$41.13M to -$44.62M, and total capital declined 7.89% from $436.56M to $402.14M.
D
Sell
3/16/2023Downgrade
Syndax Pharmaceuticals, Inc. (SNDX) was downgraded to D from D+ on 3/16/2023 due to a large decline in the total return index.
Syndax Pharmaceuticals, Inc. (SNDX) was downgraded to D from D+ on 3/16/2023 due to a large decline in the total return index.
D
Sell
3/1/2023Upgraded
Syndax Pharmaceuticals, Inc. (SNDX) was upgraded to D+ from D on 3/1/2023 due to a noticeable increase in the efficiency index, total return index and valuation index. Total capital increased 38.09% from $339.36M to $468.61M.
Syndax Pharmaceuticals, Inc. (SNDX) was upgraded to D+ from D on 3/1/2023 due to a noticeable increase in the efficiency index, total return index and valuation index. Total capital increased 38.09% from $339.36M to $468.61M.
D
Sell
2/23/2023Upgraded
Syndax Pharmaceuticals, Inc. (SNDX) was upgraded to D from D- on 2/23/2023 due to an increase in the valuation index and volatility index.
Syndax Pharmaceuticals, Inc. (SNDX) was upgraded to D from D- on 2/23/2023 due to an increase in the valuation index and volatility index.
D
Sell
2/8/2023Downgrade
Syndax Pharmaceuticals, Inc. (SNDX) was downgraded to D- from D on 2/8/2023 due to a noticeable decline in the total return index and valuation index.
Syndax Pharmaceuticals, Inc. (SNDX) was downgraded to D- from D on 2/8/2023 due to a noticeable decline in the total return index and valuation index.
D
Sell
11/7/2022Downgrade
Syndax Pharmaceuticals, Inc. (SNDX) was downgraded to D from C- on 11/7/2022 due to a large decline in the efficiency index, total return index and valuation index. Total capital declined 11.4% from $383.03M to $339.36M.
Syndax Pharmaceuticals, Inc. (SNDX) was downgraded to D from C- on 11/7/2022 due to a large decline in the efficiency index, total return index and valuation index. Total capital declined 11.4% from $383.03M to $339.36M.
C
Hold
8/10/2022Upgraded
Syndax Pharmaceuticals, Inc. (SNDX) was upgraded to C- from D+ on 8/10/2022 due to a substantial increase in the growth index and total return index. Operating cash flow increased 3.88% from -$41.93M to -$40.31M, and earnings per share increased from -$0.6302 to -$0.6246.
Syndax Pharmaceuticals, Inc. (SNDX) was upgraded to C- from D+ on 8/10/2022 due to a substantial increase in the growth index and total return index. Operating cash flow increased 3.88% from -$41.93M to -$40.31M, and earnings per share increased from -$0.6302 to -$0.6246.
D
Sell
7/25/2022Upgraded
Syndax Pharmaceuticals, Inc. (SNDX) was upgraded to D+ from D on 7/25/2022 due to a noticeable increase in the total return index.
Syndax Pharmaceuticals, Inc. (SNDX) was upgraded to D+ from D on 7/25/2022 due to a noticeable increase in the total return index.
D
Sell
6/10/2022Downgrade
Syndax Pharmaceuticals, Inc. (SNDX) was downgraded to D from D+ on 6/10/2022 due to a decline in the valuation index.
Syndax Pharmaceuticals, Inc. (SNDX) was downgraded to D from D+ on 6/10/2022 due to a decline in the valuation index.
D
Sell
5/25/2022Upgraded
Syndax Pharmaceuticals, Inc. (SNDX) was upgraded to D+ from D on 5/25/2022 due to an increase in the valuation index and total return index.
Syndax Pharmaceuticals, Inc. (SNDX) was upgraded to D+ from D on 5/25/2022 due to an increase in the valuation index and total return index.
D
Sell
5/10/2022Downgrade
Syndax Pharmaceuticals, Inc. (SNDX) was downgraded to D from C on 5/10/2022 due to a significant decline in the growth index, valuation index and solvency index. Operating cash flow declined 141.64% from $100.71M to -$41.93M, EBIT declined 138.49% from $95.75M to -$36.86M, and earnings per share declined from $1.8042 to -$0.6302.
Syndax Pharmaceuticals, Inc. (SNDX) was downgraded to D from C on 5/10/2022 due to a significant decline in the growth index, valuation index and solvency index. Operating cash flow declined 141.64% from $100.71M to -$41.93M, EBIT declined 138.49% from $95.75M to -$36.86M, and earnings per share declined from $1.8042 to -$0.6302.
C
Hold
3/4/2022Upgraded
Syndax Pharmaceuticals, Inc. (SNDX) was upgraded to C from D+ on 3/4/2022 due to a significant increase in the growth index, valuation index and efficiency index. Total revenue increased 922.84% from $12.38M to $126.58M, EBIT increased 577.98% from -$20.03M to $95.75M, and net income increased 566.1% from -$20.64M to $96.2M.
Syndax Pharmaceuticals, Inc. (SNDX) was upgraded to C from D+ on 3/4/2022 due to a significant increase in the growth index, valuation index and efficiency index. Total revenue increased 922.84% from $12.38M to $126.58M, EBIT increased 577.98% from -$20.03M to $95.75M, and net income increased 566.1% from -$20.64M to $96.2M.
D
Sell
1/27/2022Upgraded
Syndax Pharmaceuticals, Inc. (SNDX) was upgraded to D+ from D on 1/27/2022 due to an increase in the valuation index.
Syndax Pharmaceuticals, Inc. (SNDX) was upgraded to D+ from D on 1/27/2022 due to an increase in the valuation index.
D
Sell
12/22/2021Downgrade
Syndax Pharmaceuticals, Inc. (SNDX) was downgraded to D from D+ on 12/22/2021 due to a decline in the valuation index and total return index.
Syndax Pharmaceuticals, Inc. (SNDX) was downgraded to D from D+ on 12/22/2021 due to a decline in the valuation index and total return index.
D
Sell
12/7/2021Upgraded
Syndax Pharmaceuticals, Inc. (SNDX) was upgraded to D+ from D on 12/7/2021 due to an increase in the valuation index and volatility index.
Syndax Pharmaceuticals, Inc. (SNDX) was upgraded to D+ from D on 12/7/2021 due to an increase in the valuation index and volatility index.
D
Sell
11/22/2021Downgrade
Syndax Pharmaceuticals, Inc. (SNDX) was downgraded to D from D+ on 11/22/2021 due to a decline in the total return index, valuation index and solvency index. The quick ratio declined from 10.72 to 8.23.
Syndax Pharmaceuticals, Inc. (SNDX) was downgraded to D from D+ on 11/22/2021 due to a decline in the total return index, valuation index and solvency index. The quick ratio declined from 10.72 to 8.23.
D
Sell
11/15/2021Upgraded
Syndax Pharmaceuticals, Inc. (SNDX) was upgraded to D+ from D- on 11/15/2021 due to an increase in the valuation index and volatility index.
Syndax Pharmaceuticals, Inc. (SNDX) was upgraded to D+ from D- on 11/15/2021 due to an increase in the valuation index and volatility index.
D
Sell
11/8/2021Downgrade
Syndax Pharmaceuticals, Inc. (SNDX) was downgraded to D- from D on 11/8/2021 due to a decline in the valuation index and growth index.
Syndax Pharmaceuticals, Inc. (SNDX) was downgraded to D- from D on 11/8/2021 due to a decline in the valuation index and growth index.
D
Sell
9/3/2021Downgrade
Syndax Pharmaceuticals, Inc. (SNDX) was downgraded to D from D+ on 9/3/2021 due to a decline in the valuation index.
Syndax Pharmaceuticals, Inc. (SNDX) was downgraded to D from D+ on 9/3/2021 due to a decline in the valuation index.
D
Sell
8/11/2021Upgraded
Syndax Pharmaceuticals, Inc. (SNDX) was upgraded to D+ from D on 8/11/2021 due to an increase in the growth index, total return index and solvency index. EBIT increased 17.78% from -$27.16M to -$22.33M, and earnings per share increased from -$0.5383 to -$0.444.
Syndax Pharmaceuticals, Inc. (SNDX) was upgraded to D+ from D on 8/11/2021 due to an increase in the growth index, total return index and solvency index. EBIT increased 17.78% from -$27.16M to -$22.33M, and earnings per share increased from -$0.5383 to -$0.444.
D
Sell
5/13/2021Downgrade
Syndax Pharmaceuticals, Inc. (SNDX) was downgraded to D from D+ on 5/13/2021 due to a noticeable decline in the total return index, growth index and volatility index. Operating cash flow declined 44.51% from -$15.63M to -$22.59M, EBIT declined 36.77% from -$19.86M to -$27.16M, and earnings per share declined from -$0.4434 to -$0.5383.
Syndax Pharmaceuticals, Inc. (SNDX) was downgraded to D from D+ on 5/13/2021 due to a noticeable decline in the total return index, growth index and volatility index. Operating cash flow declined 44.51% from -$15.63M to -$22.59M, EBIT declined 36.77% from -$19.86M to -$27.16M, and earnings per share declined from -$0.4434 to -$0.5383.
D
Sell
4/20/2021Upgraded
Syndax Pharmaceuticals, Inc. (SNDX) was upgraded to D+ from D on 4/20/2021 due to an increase in the total return index and valuation index.
Syndax Pharmaceuticals, Inc. (SNDX) was upgraded to D+ from D on 4/20/2021 due to an increase in the total return index and valuation index.
D
Sell
10/16/2020Downgrade
Syndax Pharmaceuticals, Inc. (SNDX) was downgraded to D from D+ on 10/16/2020 due to a decline in the valuation index.
Syndax Pharmaceuticals, Inc. (SNDX) was downgraded to D from D+ on 10/16/2020 due to a decline in the valuation index.
D
Sell
10/1/2020Upgraded
Syndax Pharmaceuticals, Inc. (SNDX) was upgraded to D+ from D on 10/1/2020 due to a large increase in the solvency index, total return index and growth index. The quick ratio increased from 5.42 to 15.24, debt to equity declined from 0.38 to 0.14, and earnings per share increased from -$0.5576 to -$0.4202.
Syndax Pharmaceuticals, Inc. (SNDX) was upgraded to D+ from D on 10/1/2020 due to a large increase in the solvency index, total return index and growth index. The quick ratio increased from 5.42 to 15.24, debt to equity declined from 0.38 to 0.14, and earnings per share increased from -$0.5576 to -$0.4202.
D
Sell
5/1/2020Upgraded
Syndax Pharmaceuticals, Inc. (SNDX) was upgraded to D from D- on 5/1/2020 due to a large increase in the growth index, total return index and volatility index.
Syndax Pharmaceuticals, Inc. (SNDX) was upgraded to D from D- on 5/1/2020 due to a large increase in the growth index, total return index and volatility index.
D
Sell
6/25/2018Downgrade
Syndax Pharmaceuticals, Inc. (SNDX) was downgraded to D- from D on 6/25/2018 due to a decline in the volatility index and total return index.
Syndax Pharmaceuticals, Inc. (SNDX) was downgraded to D- from D on 6/25/2018 due to a decline in the volatility index and total return index.
D
Sell
5/15/2018Upgraded
Syndax Pharmaceuticals, Inc. (SNDX) was upgraded to D from D- on 5/15/2018 due to an increase in the volatility index and valuation index.
Syndax Pharmaceuticals, Inc. (SNDX) was upgraded to D from D- on 5/15/2018 due to an increase in the volatility index and valuation index.
D
Sell
4/23/2018Downgrade
Syndax Pharmaceuticals, Inc. (SNDX) was downgraded to D- from D on 4/23/2018 due to a decline in the volatility index.
Syndax Pharmaceuticals, Inc. (SNDX) was downgraded to D- from D on 4/23/2018 due to a decline in the volatility index.
D
Sell
4/2/2018Upgraded
Syndax Pharmaceuticals, Inc. (SNDX) was upgraded to D from D- on 4/2/2018 due to a noticeable increase in the growth index, total return index and volatility index. Total revenue increased 291.15% from $305 to $1.19M.
Syndax Pharmaceuticals, Inc. (SNDX) was upgraded to D from D- on 4/2/2018 due to a noticeable increase in the growth index, total return index and volatility index. Total revenue increased 291.15% from $305 to $1.19M.
D
Sell
11/28/2017Downgrade
Syndax Pharmaceuticals, Inc. (SNDX) was downgraded to D- from D on 11/28/2017 due to a decline in the volatility index and total return index.
Syndax Pharmaceuticals, Inc. (SNDX) was downgraded to D- from D on 11/28/2017 due to a decline in the volatility index and total return index.
D
Sell
11/13/2017Upgraded
Syndax Pharmaceuticals, Inc. (SNDX) was upgraded to D from D- on 11/13/2017 due to an increase in the volatility index, growth index and efficiency index. Operating cash flow increased 13.72% from -$11.8M to -$10.18M, and earnings per share increased from -$0.6995 to -$0.6784.
Syndax Pharmaceuticals, Inc. (SNDX) was upgraded to D from D- on 11/13/2017 due to an increase in the volatility index, growth index and efficiency index. Operating cash flow increased 13.72% from -$11.8M to -$10.18M, and earnings per share increased from -$0.6995 to -$0.6784.
D
Sell
12/1/2016Upgraded
Syndax Pharmaceuticals, Inc. (SNDX) was upgraded to D- from E on 12/01/2016.
Syndax Pharmaceuticals, Inc. (SNDX) was upgraded to D- from E on 12/01/2016.
E
Sell
11/17/2016Downgrade
Syndax Pharmaceuticals, Inc. (SNDX) was downgraded to E from E+ on 11/17/2016 due to a significant decline in the efficiency index, growth index and volatility index. EBIT declined 80.67% from -$8.43M to -$15.24M, net income declined 79.1% from -$8.36M to -$14.97M, and earnings per share declined from -$0.4704 to -$0.8363.
Syndax Pharmaceuticals, Inc. (SNDX) was downgraded to E from E+ on 11/17/2016 due to a significant decline in the efficiency index, growth index and volatility index. EBIT declined 80.67% from -$8.43M to -$15.24M, net income declined 79.1% from -$8.36M to -$14.97M, and earnings per share declined from -$0.4704 to -$0.8363.
E
Sell
9/1/2016Upgraded
Syndax Pharmaceuticals, Inc. (SNDX) was upgraded to E+ from E on 9/1/2016 due to an increase in the growth index, efficiency index and total return index. Earnings per share increased from -$2.8466 to -$0.4704, net income increased 19.09% from -$10.33M to -$8.36M, and EBIT increased 3.64% from -$8.75M to -$8.43M.
Syndax Pharmaceuticals, Inc. (SNDX) was upgraded to E+ from E on 9/1/2016 due to an increase in the growth index, efficiency index and total return index. Earnings per share increased from -$2.8466 to -$0.4704, net income increased 19.09% from -$10.33M to -$8.36M, and EBIT increased 3.64% from -$8.75M to -$8.43M.
E
Sell
8/11/2016Upgraded
Syndax Pharmaceuticals, Inc. (SNDX) was upgraded to E from E- on 8/11/2016 due to an increase in the volatility index.
Syndax Pharmaceuticals, Inc. (SNDX) was upgraded to E from E- on 8/11/2016 due to an increase in the volatility index.
E
Sell
7/27/2016Downgrade
Syndax Pharmaceuticals, Inc. (SNDX) was downgraded to E- from E on 7/27/2016 due to a decline in the volatility index and total return index.
Syndax Pharmaceuticals, Inc. (SNDX) was downgraded to E- from E on 7/27/2016 due to a decline in the volatility index and total return index.
E
Sell
7/12/2016Upgraded
Syndax Pharmaceuticals, Inc. (SNDX) was upgraded to E from E- on 7/12/2016 due to an increase in the volatility index.
Syndax Pharmaceuticals, Inc. (SNDX) was upgraded to E from E- on 7/12/2016 due to an increase in the volatility index.
E
Sell
6/27/2016Downgrade
Syndax Pharmaceuticals, Inc. (SNDX) was downgraded to E- from E on 6/27/2016 due to a significant decline in the volatility index.
Syndax Pharmaceuticals, Inc. (SNDX) was downgraded to E- from E on 6/27/2016 due to a significant decline in the volatility index.
E
Sell
5/26/2016None
Syndax Pharmaceuticals, Inc. (SNDX) was downgraded to E from U on 05/26/2016.
Syndax Pharmaceuticals, Inc. (SNDX) was downgraded to E from U on 05/26/2016.
NASDAQ
04/08/2025 4:00PM Eastern
Quotes delayed
